

September 27, 2016

To.

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra East. Mumbai-400051

Scrip Code: JUBILANT

Dear Sir/Madam,

Sub: Clarification JUBILANT

This has reference to your email dated September 26, 2016 on the captioned subject seeking clarification on an announcement submitted to the Stock Exchanges vide our letter dated September 23, 2016.

In this reference, our clarifications to your queries mentioned in your aforesaid email are as under:


- Clarification to Query No. 1: The said issuance is a benchmark offering of unsecured high yield bonds outside India by our material wholly-owned subsidiary, Jubilant Pharma Limited, Singapore ('JPL') to identified institutional investors outside India, under Regulation S of the U.S. Securities Act, 1933 and is not a public offering in India.
- Clarification to Query No. 2: JPL is currently undertaking meetings with potential investors pursuant to the approval of its Board of Directors for the benchmark offering of unsecured high yield bonds on September 23, 2016. Upon the completion of these investors meetings and the book building process, JPL will price such issuance of high yield bonds. We will intimate the stock exchanges upon completion of the pricing of the bonds once JPL has determined the final terms of such high yield bonds, including the total amount of such securities.

The above is for your information and records.

Thanking You,

Yours Sincerely, For Jubilant Life Sciences Limited Sciences

Rajiv Shah Company Secretary





Fax: +91 120 4234895-96 www.jubl.com

Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223, CIN: L24116UP1978PLC004624